✦ LIBER ✦

Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial

✍ Scribed by P. De Simone; F. Nevens; L. De Carlis; H. J. Metselaar; S. Beckebaum; F. Saliba; S. Jonas; D. Sudan; J. Fung; L. Fischer; C. Duvoux; K. D. Chavin; B. Koneru; M. A. Huang; W. C. Chapman; D. Foltys; S. Witte; H. Jiang; J. M. Hexham; G. Junge; for the H2304 Study Group

Book ID: 117963586
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 702 KB
Volume: 12
Category: Article
ISSN: 1600-6135
DOI: 10.1111/j.1600-6143.2012.04212.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early Withdrawal of Calcineurin Inhibito

Early Withdrawal of Calcineurin Inhibitors and Everolimus Monotherapy in de novo Liver Transplant Recipients Preserves Renal Function

✍ M. Masetti; R. Montalti; G. Rompianesi; M. Codeluppi; R. Gerring; A. Romano; B. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 358 KB

132: Everolimus Introduction with CNI Mi

132: Everolimus Introduction with CNI Minimization Significantly Improves Renal Function in Thoracic Transplant Recipients: A Scandinavian Multicenter, Randomized Study

✍ L. Gullestad; B. Rundqvist; S.A. Mortensen; H. Eiskjaer; G.C. Riise; L. Mared; O 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 62 KB

A randomized, prospective, pharmacoecono

A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients

✍ Surendra Shenoy; Karen L. Hardinger; Jeffrey Crippin; Kevin Korenblat; Mauricio 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB 👁 1 views

Two-hour postdose cyclosporine (C2) monitoring is becoming an accepted method of therapeutic drug monitoring, although it is not known whether C2 monitoring is superior to tacrolimus (FK)-based immunosuppression. The purpose of this trial was to compare the safety, efficacy, and pharmacoeconomics of

Improvement of renal function after the

Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction

✍ Javier F. Castroagudín; Esther Molina; Rafael Romero; Esteban Otero; Santiago To 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 1 views

Chronic renal dysfunction is a frequent and severe complication in solid-organ transplant recipients. Calcineurin inhibitors (CNIs) are the main pathogenic factors of renal dysfunction. Switching from CNIs to nonnephrotoxic drugs, such as mammalian target of rapamycin inhibitors (everolimus and siro

15: Results of a 12-Month, Multicenter,

15: Results of a 12-Month, Multicenter, Randomized Trial of Everolimus with Reduced-Exposure Cyclosporine Versus MMF and Standard-Exposure Cyclosporine in De Novo Cardiac Transplant Recipients

✍ H. Lehmkuhl; U. Livi; J. Arizon; M. Viganò; C. Magelli; P. Boissonnat; G. Gerosa 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 112 KB

A randomized controlled trial of late co

A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function

✍ Christopher J.E. Watson; Alexander E.S. Gimson; Graeme J. Alexander; Michael E.D 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB 👁 1 views

Renal impairment is common in patients after liver transplantation and is attributable in large part to the use of calcineurin inhibitor (CNI)-based immunosuppression. We sought to determine whether conversion to sirolimus-based immunosuppression was associated with improved renal function. In a sin